Spravato, a nasal spray esketamine, was found to work better than Seroquel for treatment-resistant depression, a study in the New England Journal of Medicine finds.

Meeting Coverage > Psych Congress Esketamine Also Effective Without Adjunctive Antidepressant — Trial data may expand use, with "opportunity to truly individualize treatment" by Kristen Monaco ...

Esketamine, the (S) enantiomer of racemic ketamine, is FDA-approved for adults with TRD and adults with MDD with suicidal thoughts or actions in combination with an oral antidepressant.

Credit: pxhere.com Esketamine plus SNRI cohort showed better survival probability than esketamine pls SSRI group. Credit: JAMA Psychiatry (2025). DOI: 10.1001/jamapsychiatry.2025.0200 ...

Esketamine nasal spray, administered in combination with either a selective serotonin reuptake inhibitor (SSRI) or a serotonin–norepinephrine reuptake inhibitor (SNRI), is the only treatment ...

Nasal esketamine spray is more effective than an extended-release antipsychotic, when both are taken in combination with SSRIs and SNRIs, in treatment-resistant depression, a study found.

Johnson & Johnson announced that it has submitted a supplemental new drug application for the approval of esketamine nasal spray as a monotherapy for adults with treatment-resistant depression.If ...

They included 55,480 participants with TRD, half of whom were treated with esketamine plus an SNRI (58.6% women; mean age, 45.9 years) and the other half with esketamine plus an SSRI (57.7% women ...

Esketamine is the first monotherapy for MDD with inadequate response to two oral antidepressants, approved after a priority FDA review. Clinical trials showed esketamine's rapid efficacy, with 22. ...

Spravato, a nasal spray esketamine, was found to work better than Seroquel for treatment-resistant depression, a study in the New England Journal of Medicine finds.